News >

Final Results of Abiraterone Acetate in Advanced Prostate Cancer Show Significantly Improved Survival

Ben Leach
Published: Tuesday, Sep 18, 2012

Abiraterone acetate (Zytiga)A final analysis of a phase III trial comparing abiraterone acetate plus prednisone with a placebo in patients with metastatic castration-resistant prostate cancer (mCRPC) found that abiraterone significantly improved overall survival with positive responses seen in several subgroups of patients.

Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase III study [published online ahead of print September 18, 2012]. Lancet Oncol. DOI:10.1016/S0140-6736(08)61345-8.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x